Laird Norton Wetherby Trust Company LLC Acquires Shares of 11,000 Accolade, Inc. (NASDAQ:ACCD)

Laird Norton Wetherby Trust Company LLC purchased a new position in Accolade, Inc. (NASDAQ:ACCD) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,000 shares of the company’s stock, valued at approximately $38,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of ACCD. Nisa Investment Advisors LLC lifted its stake in Accolade by 15,113.1% in the 4th quarter. Nisa Investment Advisors LLC now owns 55,680 shares of the company’s stock worth $190,000 after purchasing an additional 55,314 shares in the last quarter. Barclays PLC lifted its position in Accolade by 164.4% during the third quarter. Barclays PLC now owns 139,901 shares of the company’s stock worth $539,000 after buying an additional 86,981 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Accolade during the fourth quarter worth approximately $120,000. Savant Capital LLC lifted its position in Accolade by 182.1% during the fourth quarter. Savant Capital LLC now owns 52,794 shares of the company’s stock worth $181,000 after buying an additional 34,082 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Accolade by 1.7% during the 4th quarter. Rhumbline Advisers now owns 115,136 shares of the company’s stock worth $394,000 after acquiring an additional 1,967 shares during the period. 84.99% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on ACCD. Stephens reiterated an “equal weight” rating and set a $7.03 price target on shares of Accolade in a report on Wednesday, February 12th. Piper Sandler downgraded shares of Accolade from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Thirteen equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $6.51.

Accolade Price Performance

Shares of ACCD opened at $7.02 on Monday. The company’s 50-day moving average price is $7.01 and its 200 day moving average price is $5.68. The firm has a market cap of $575.59 million, a P/E ratio of -3.12 and a beta of 2.10. Accolade, Inc. has a 12-month low of $3.08 and a 12-month high of $8.05. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 0.67.

Accolade Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.